Identifying Sepsis Subtypes from Routine Clinical Data

Abstract

efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiency. JAMA 1988;260:1259–1264. 4. Soy D, de la Roza C, Lara B, Esquinas C, Torres A, Miravitlles M. Alpha-1-antitrypsin deficiency: optimal therapeutic regimen based on population pharmacokinetics. Thorax 2006;61: 1059–1064. 5. Barker AF, Iwata-Morgan I, Oveson L, Roussel R. Pharmacokinetic study of alpha1-antitrypsin infusion in alpha1-antitrypsin deficiency. Chest 1997;112:607–613. 6. Petrache I, Fijalkowska I, Medler TR, Skirball J, Cruz P, Zhen L, et al. alpha-1 antitrypsin inhibits caspase-3 activity, preventing lung endothelial cell apoptosis. Am J Pathol 2006;169: 1155–1166. 7. Sohrab S, Petrusca DN, Lockett AD, Schweitzer KS, Rush NI, Gu Y, et al. Mechanism of alpha-1 antitrypsin endocytosis by lung endothelium. FASEB J 2009;23:3149–3158. 8. Lockett AD, Brown MB, Santos-Falcon N, Rush NI, Oueini H, Oberle AJ, et al. Active trafficking of alpha 1 antitrypsin across the lung endothelium. PLoS One 2014;9:e93979. 9. Lockett AD, Petrusca DN, Justice MJ, Poirier C, Serban KA, Rush NI, et al. Scavenger receptor class B, type I-mediated uptake of A1AT by pulmonary endothelial cells. Am J Physiol Lung Cell Mol Physiol 2015; 309:L425–L434. 10. Franciosi AN, McCarthy C, McElvaney NG. The efficacy and safety of inhaled human a-1 antitrypsin in people with a-1 antitrypsin deficiency-related emphysema. Expert Rev Respir Med 2015;9: 143–151. 11. Baranovski BM, Schuster R, Nisim O, Brami I, Lior Y, Lewis EC. Alpha-1 antitrypsin substitution for extrapulmonary conditions in alpha-1 antitrypsin deficient patients. Chronic Obstr Pulm Dis (Miami) 2018;5: 267–276. 12. Chapman KR, Burdon JG, Piitulainen E, Sandhaus RA, Seersholm N, Stocks JM, et al.; RAPID Trial Study Group. Intravenous augmentation treatment and lung density in severe a1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet 2015;386:360–368. 13. Stiles KM, Sondhi D, Kaminsky SM, De BP, Rosenberg JB, Crystal RG. Intrapleural gene therapy for alpha-1 antitrypsin deficiency-related lung disease. Chronic Obstr Pulm Dis (Miami) 2018;5:244–257. 14. Connolly B, Isaacs C, Cheng L, Asrani KH, Subramanian RR. SERPINA1 mRNA as a treatment for alpha-1 antitrypsin deficiency. J Nucleic Acids 2018;2018:8247935. 15. Gruntman AM, Flotte TR. Therapeutics: gene therapy for alpha-1 antitrypsin deficiency. Methods Mol Biol 2017;1639: 267–275. 16. Lomas DA. New therapeutic targets for alpha-1 antitrypsin deficiency. Chronic Obstr Pulm Dis (Miami) 2018;5:233–243.